NERVGEN PHARMA CORP.

NERVGEN PHARMA CORP.

Share · CA64082X2032 · NGEN · A2QP3D (XTSX)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NERVGEN PHARMA CORP.
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
0
0
0
No Price
28.04.2026 20:03
Current Prices from NERVGEN PHARMA CORP.
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
NGEN
USD
28.04.2026 20:03
3,93 USD
0,08 USD
+2,00 %
IEXG: IEX
IEX
NGEN
USD
28.04.2026 19:57
3,89 USD
0,03 USD
+0,91 %
XDQU: Quotrix
Quotrix
NERVGE32.DUSD
EUR
28.04.2026 05:27
3,28 EUR
-0,24 EUR
-6,82 %
XDUS: Düsseldorf
Düsseldorf
NERVGE32.DUSB
EUR
27.04.2026 06:13
3,26 EUR
-
XHAM: Hamburg
Hamburg
NERVGE32.HAMB
EUR
23.04.2026 06:13
3,44 EUR
-
Share Float & Liquidity
Free Float 83,77 %
Shares Float 66,35 M
Shares Outstanding 79,21 M
Company Profile for NERVGEN PHARMA CORP. Share
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.

Company Data

Name NERVGEN PHARMA CORP.
Company NervGen Pharma Corp.
Symbol NGEN
Website https://www.nervgen.com
Primary Exchange XTSX Frankfurt
WKN A2QP3D
ISIN CA64082X2032
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Adam H. Rogers
Market Capitalization 408 Mio
Country Canada
Currency EUR
Employees 0,0 T
Address 2955 Virtual Way, V5M 4X6 Vancouver
IPO Date 2019-03-15

Ticker Symbols

Name Symbol
Over The Counter NGENF
Düsseldorf NERVGE32.DUSB
Frankfurt 9UA.F
Hamburg NERVGE32.HAMB
NASDAQ NGEN
Quotrix NERVGE32.DUSD
TSX-V NGEN.V
More Shares
Investors who hold NERVGEN PHARMA CORP. also have the following shares in their portfolio:
LBBW DAI BOA SZ P 15/22
LBBW DAI BOA SZ P 15/22 Bond
LLOYDS BANKING GROUP PLC 6.413% NON-CUM FXD/FLTG RTE PREF SHS
LLOYDS BANKING GROUP PLC 6.413% NON-CUM FXD/FLTG RTE PREF SHS Bond